The clinical effect of 4-(2'-nitrophenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1,4-dihydropyridine (BAY a 1040) on angina pectoris evaluated by sequential analysis.
D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003998:Dicarboxylic Acids / Q000627:therapeutic use; D004562:Electrocardiography; D005080:Exercise Test; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009578:Nitrobenzenes / Q000627:therapeutic use*; D005996:Nitroglycerin / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy; D010919:Placebos; D011725:Pyridines / Q000627:therapeutic use*; D013997:Time Factors; D014665:Vasodilator Agents / Q000627:therapeutic use*
D003998:Dicarboxylic Acids; D009578:Nitrobenzenes; D010919:Placebos; D011725:Pyridines; D014665:Vasodilator Agents; D005996:Nitroglycerin